select a format

Single User License
USD 2000 INR 130040
Site License
USD 4000 INR 260080
Corporate User License
USD 6000 INR 390120


Request a quote
Request a Customized research
Request for Sample Report


Recent Viewed Reports

Why Ken Reasearch?


The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements.... "Senior Associate, Booz Allen Hamilton"

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

Cryptosporidiosis-Pipeline Review, H1 2015

Cryptosporidiosis-Pipeline Review, H1 2015

  • Products Id :- GMDHC6767IDB
  • |
  • Pages: 34
  • |
  • May 2015
  • |
  • |
  Request for Sample Report

Executive Summary

Cryptosporidiosis-Pipeline Review, H1 2015


Global Markets Direct's, 'Cryptosporidiosis-Pipeline Review, H1 2015', provides an overview of the Cryptosporidiosis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Cryptosporidiosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cryptosporidiosis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides a snapshot of the global therapeutic landscape of Cryptosporidiosis

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Cryptosporidiosis and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Cryptosporidiosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Cryptosporidiosis pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Cryptosporidiosis

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Cryptosporidiosis pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
ankur [@]

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Cryptosporidiosis Overview 6

Therapeutics Development 7

Pipeline Products for Cryptosporidiosis-Overview 7

Pipeline Products for Cryptosporidiosis-Comparative Analysis 8

Cryptosporidiosis-Therapeutics under Development by Companies 9

Cryptosporidiosis-Therapeutics under Investigation by Universities/Institutes 10

Cryptosporidiosis-Pipeline Products Glance 11

Early Stage Products 11

Cryptosporidiosis-Products under Development by Companies 12

Cryptosporidiosis-Products under Investigation by Universities/Institutes 13

Cryptosporidiosis-Companies Involved in Therapeutics Development 14

Romark Laboratories, L.C. 14

Cryptosporidiosis-Therapeutics Assessment 15

Assessment by Monotherapy Products 15

Assessment by Target 16

Assessment by Mechanism of Action 18

Assessment by Route of Administration 20

Assessment by Molecule Type 21

Drug Profiles 23

cryptosporidiosis vaccine-Drug Profile 23

Product Description 23

Mechanism of Action 23

R&D Progress 23

cryptosporidiosis vaccine (divalent)-Drug Profile 24

Product Description 24

Mechanism of Action 24

R&D Progress 24

DBAF-201-Drug Profile 25

Product Description 25

Mechanism of Action 25

R&D Progress 25

Small Molecules for Cryptosporidiosis-Drug Profile 26

Product Description 26

Mechanism of Action 26

R&D Progress 26

P-131-Drug Profile 27

Product Description 27

Mechanism of Action 27

R&D Progress 27

RM-5038-Drug Profile 28

Product Description 28

Mechanism of Action 28

R&D Progress 28

Small Molecules to Inhibit DHFR for Infectious Diseases-Drug Profile 29

Product Description 29

Mechanism of Action 29

R&D Progress 29

Small Molecules to Inhibit IMPDH for Cryptosporidiosis-Drug Profile 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

Cryptosporidiosis-Dormant Projects 32

Appendix 33

Methodology 33

Coverage 33

Secondary Research 33

Primary Research 33

Expert Panel Validation 33

Contact Us 33

Disclaimer 34

List of Tables

Number of Products under Development for Cryptosporidiosis, H1 2015 7

Number of Products under Development for Cryptosporidiosis-Comparative Analysis, H1 2015 8

Number of Products under Development by Companies, H1 2015 9

Number of Products under Investigation by Universities/Institutes, H1 2015 10

Comparative Analysis by Early Stage Development, H1 2015 11

Products under Development by Companies, H1 2015 12

Products under Investigation by Universities/Institutes, H1 2015 13

Cryptosporidiosis-Pipeline by Romark Laboratories, L.C., H1 2015 14

Assessment by Monotherapy Products, H1 2015 15

Number of Products by Stage and Target, H1 2015 17

Number of Products by Stage and Mechanism of Action, H1 2015 19

Number of Products by Stage and Route of Administration, H1 2015 20

Number of Products by Stage and Molecule Type, H1 2015 22

Cryptosporidiosis-Dormant Projects, H1 2015 32

List of Figures

Number of Products under Development for Cryptosporidiosis, H1 2015 7

Number of Products under Development for Cryptosporidiosis-Comparative Analysis, H1 2015 8

Number of Products under Development by Companies, H1 2015 9

Number of Products under Investigation by Universities/Institutes, H1 2015 10

Comparative Analysis by Early Stage Products, H1 2015 11

Assessment by Monotherapy Products, H1 2015 15

Number of Products by Top 10 Targets, H1 2015 16

Number of Products by Stage and Top 10 Targets, H1 2015 17

Number of Products by Top 10 Mechanism of Actions, H1 2015 18

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 19

Number of Products by Top 10 Molecule Types, H1 2015 21

Number of Products by Stage and Top 10 Molecule Types, H1 2015 22

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@]

Romark Laboratories, L.C

Cryptosporidiosis Therapeutic Products under Development, Key Players in Cryptosporidiosis Therapeutics, Cryptosporidiosis Pipeline Overview, Cryptosporidiosis Pipeline, Cryptosporidiosis Pipeline Assessment

Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

query [@]